Related Experiment Video
Updated: May 2, 2026
08:10
Capture and Release of Viable Circulating Tumor Cells from Blood
Published on: October 28, 2016
8.2K
TCTP as therapeutic target in cancers
Julie Acunzo1, Virginie Baylot1, Alan So2
1(a)Inserm, U1068, CRCM, Marseille F-13009, France; (b)Institut Paoli-Calmettes, Marseille F-13009, France; (c)Aix-Marseille Univ., Marseille F-13284, France; (d)CNRS, UMR7258, Marseille F-13009, France.
Cancer Treatment Reviews
|March 22, 2014
Summary
The translationally controlled tumor protein (TCTP) is a key regulator in cell functions and cancer. This review explores TCTP
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- The translationally controlled tumor protein (TCTP) is a highly conserved eukaryotic protein.
- TCTP is localized in both cytoplasm and nucleus, with expression varying across tissues and responding to extracellular stimuli.
- It interacts with itself and other proteins like MCL1 and p53, influencing critical cellular processes.
Purpose of the Study:
- To review the pathways regulated by TCTP.
- To discuss current strategies for inhibiting TCTP in cancer treatment.
Main Methods:
- Literature review of TCTP's role in cellular functions and disease.
- Analysis of TCTP's involvement in physiological and stress responses.
- Examination of TCTP's association with malignancy and chemoresistance.
Main Results:
- TCTP is implicated in cell proliferation, cell death, immune responses, stress response, and tumor reversion.
- Elevated TCTP expression correlates with increased malignancy and chemoresistance.
- TCTP's multifaceted roles highlight its significance in cancer biology.
Conclusions:
- TCTP is a critical protein involved in fundamental cellular processes and cancer development.
- Targeting TCTP presents a promising therapeutic strategy for various cancerous diseases.
- Further research into TCTP-regulated pathways and inhibition methods is warranted.
Related Concept Videos
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
02:57Targeted Cancer Therapies
1.4K
1.4K
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81